Given the ability of the TPTPB to detect prostate cancer at significantly higher rates than TRUS biopsies (8–12), we questioned whether we should move away from TRUS biopsies to TPTPB and whether PSA is actually a more specific biomarker for prostate cancer detection than had been previously thought. Here, KLK3 is linked to prostate cancer.